AYOXXA Biosystems, an international biotech company based in Cologne, Germany and Singapore has developed a proprietary technology platform for multiplexed protein analysis. Core to the cutting-edge system is a bead-based technology that yields 10,000-fold more data points than a standard ELISA. Together with the lowest sample volume in multiplex protein analysis history, very good accuracy and data robustness, high data throughput and readout with equipment existing already in your lab, AYOXXA will innovate biomedical research, pharmacological screening and preclinical diagnostics development. Its „in-situ encoded bead array“ (IEBA) technology allows industry and university users to realize the full potential of proteomics reliably as well as resource and cost efficiently.
AYOXXA stands for leveraging success in proteomics.
AYOXXA offers a multiplexed protein analysis platform situated at the heart of a medical revolution: the decoding of the human proteome, which will help us to understand and cure most known diseases.
Proteomics will play an important part in personalized medicine that will replace the more and more outdated “one drug fits all” model with a more tailored approach.
Therefore R&D will depend on innovative technologies for protein analysis. AYOXXA has developed such a platform, which allows to simultaneously measure large amounts of proteins and biomolecular analytes. The biochip precisely identifies and quantifies proteins, including markers for cancer, allergies, cardiovascular or infectious diseases.
The AYOXXA technology innovates proteomics, as it offers revolutionary customer benefits: the smallest sample volume required in protein multiplexing, reduced degree of complexity and sources of error.